Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Brainstorm Cell Therapeutics stock opened at $1.56 on Friday. The business has a 50 day moving average of $1.97 and a 200-day moving average of $2.42. The company has a market capitalization of $8.90 million, a P/E ratio of -0.33 and a beta of 0.26. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.